University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial CTSU-EA2165


A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Type: Treatment
Phase: Phase II
Status: Open to Accrual
Treatments: Chemotherapy: Systemic, Immunotherapy
Randomized: Yes
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Syma Iqbal, M.D.
Other Trial Staff:  Fahim Raian, D.M., Jiayi Jiang, D.M., Raluca Agafitei, Coordinator, Marile Garcia, Coordinator, Noureddine Miloud, D.M., Yanli Wang, D.M., Rabia Rehman, Coordinator, Diana Oganyesyan, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.